Pancreatic Cancer Research

ResearcherTokyo Medical and Dental UniversityActive in the last 2 years

Toshiro Ogura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2711-6076; OpenAlex author ID A5015860403. Sources: OpenAlex.

Their work

Papers
9 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 4 papers · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 9

  1. Optimal treatment strategy for patients with pancreatic cancer having positive peritoneal cytology: A nationwide multicenter retrospective cohort study supervi… Co-author DOI 10.1002/jhbp.12074↗
  2. Prognostic Value of Peritoneal Lavage Cytology in Potentially Resectable Pancreatic Cancer Stratified by Cytologic Status. First author DOI 10.21873/cdp.10221↗
  3. Optimal Region of Lymph Node Dissection in Distal Pancreatectomy for Left-Sided Pancreatic Cancer Based on Tumor Location. First author DOI 10.1245/s10434-021-11108-5↗
  4. ASO Author Reflections: Optimal Region of Lymph Node Dissection in Distal Pancreatectomy for Pancreatic Cancer Based on Tumor Location: Should We Dissect Non-P… First author DOI 10.1245/s10434-021-11115-6↗
  5. Strategy of Pancreatectomies for Pancreatic Ductal Adenocarcinoma in Patients with a History of Gastrectomy. First author DOI 10.1620/tjem.2022.j009↗
  6. Importance of an appropriate number of examined lymph nodes in patients with pancreatic cancer-the more the better? Co-author DOI 10.21037/hbsn-22-163↗
  7. C646 inhibits G2/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer. Co-author DOI 10.1038/s41598-021-89530-8↗
  8. Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0252917↗
  9. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality. Co-author DOI 10.1002/ijc.32072↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Amane Takahashi · 5 shared papers, 2022–2023 · strength 1.10
  2. Hiroyuki Ishida · 4 shared papers, 2022–2023 · strength 0.84
  3. Minoru Tanabe · 5 shared papers, 2019–2023 · strength 0.67
  4. Yoshiyuki Kawashima · 3 shared papers, 2022–2023 · strength 0.57
  5. Katsumi Amikura · 2 shared papers, 2022 · strength 0.43
  6. Ryoichi Miyamoto · 2 shared papers, 2022–2023 · strength 0.35
  7. Hiroaki Ono · 3 shared papers, 2019–2021 · strength 0.32
  8. Daisuke Ban · 3 shared papers, 2019–2021 · strength 0.32
  9. Kosuke Ogawa · 3 shared papers, 2019–2021 · strength 0.32
  10. Tomotaka Kato · 2 shared papers, 2021 · strength 0.24
  11. Shinji Tanaka · 2 shared papers, 2021 · strength 0.24
  12. Shuichi Watanabe · 2 shared papers, 2019–2021 · strength 0.20
  13. Kenichi Hakamada · 1 shared paper, 2025 · strength 0.19
  14. Sohei Satoi · 1 shared paper, 2025 · strength 0.19
  15. Masamichi Hayashi · 1 shared paper, 2025 · strength 0.19
  16. Masaaki Hidaka · 1 shared paper, 2025 · strength 0.19
  17. Hirofumi Akita · 1 shared paper, 2025 · strength 0.19
  18. Masamichi Mizuma · 1 shared paper, 2025 · strength 0.19
  19. Kyohei Ariake · 1 shared paper, 2025 · strength 0.19
  20. Hiroshi Kurahara · 1 shared paper, 2025 · strength 0.19
  21. Naoto Yamamoto · 1 shared paper, 2025 · strength 0.19
  22. Etsuro Hatano · 1 shared paper, 2025 · strength 0.19
  23. Ippei Matsumoto · 1 shared paper, 2025 · strength 0.19
  24. Michiaki Unno · 1 shared paper, 2025 · strength 0.19
  25. Satoshi Hirano · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.